Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 4/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10115831 | 0.88 | HDAC1 (0.52) | HDAC1HDAC2HDAC3THRBRAB9A | |
| SCHEMBL10115010 | 0.85 | HDAC1 (0.52) | HDAC1HDAC2HDAC3RAB9ANPC1 | |
| SCHEMBL10116019 | 0.81 | EPHX2 (0.46) | THRBRAB9ANPC1MAPK1CCR8 | |
| SCHEMBL14627798 | 0.79 | GRIA2 (0.37) | HDAC1HDAC2HDAC3GRIA2 | |
| SCHEMBL10116153 | 0.78 | GRIA2 (0.39) | THRBRAB9ANPC1MAPK1CCR8 | |
| SCHEMBL13564910 | 0.78 | GRIA2 (0.38) | HDAC1HDAC2HDAC3GRIA2 | |
| SCHEMBL17090412 | 0.78 | GRIA2 (0.38) | HDAC1HDAC2HDAC3GRIA2 | |
| SCHEMBL10116053 | 0.78 | HRH3 (0.44) | THRBRAB9ANPC1MAPK1CCR8 | |
| SCHEMBL10116148 | 0.77 | CCR8 (0.47) | THRBRAB9ANPC1MAPK1CCR8 | |
| SCHEMBL10116146 | 0.76 | HRH3 (0.44) | THRBRAB9ANPC1MAPK1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | HDAC1 1995/4885HDAC2 1548/4885HDAC3 664/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | HDAC1 1703/4885HDAC2 1458/4885HDAC3 489/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | HDAC1 2021/4885HDAC2 1524/4885HDAC3 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.